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Introduction
Italian company Cosmed has a reputation for labora-
tory-based medical device products which is founded 
on sound IP. The market is competitive, with a limited 
number of players, so reputation is critical to securing 
a leading role. Patents assure customers that products 
are innovative. They increase visibility and recognition, 
and justify premium prices. When co-operating with 
external partners, IP also makes everyone’s boundaries 
clear from the start and prevents any confusion moving 
forward. Medical technology must comply with regula-
tory requirements in order to enter the market. This 
takes time, so Cosmed chooses to establish IP early to 
safeguard its investments.
Founded in 1980, Cosmed has become a leader in the fields of industrial design, the development and manufacture of diagnostic equipment, and 
scientific research in the med-tech industry. With a 
business model based on direct and network sales, it 
has established subsidiaries in Germany, France, Swit-
zerland, the U.S., China, and Australia, and has distrib-
utors in Russia, Brazil and Korea.
The company’s wide range of products includes spirom-
eters, portable systems for the analysis of respiratory 
function and nutrition, and systems for the execution 
of cardiopulmonary exercise testing for metabolism and 
body composition. They can be used in a variety of fields, 
including pulmonary sports medicine, cardiology, clinical 
nutrition, rehabilitation and occupational medicine and 
pedagogic physiology.
One of the innovations that Cosmed has launched 
on the world market since 2005 is the FitMate se-
ries, a set of products for measuring resting metabolic 
rate, maximum oxygen consumption and spirometric 
parameters. Competitive pricing, ease of use and low 
maintenance requirements have allowed Cosmed to 
penetrate market sectors that were previously inacces-
sible, such as fitness and private dietetics.
In 2006, Cosmed updated its entire range of sta-
tionary laboratory testing products. It introduced in-
novative modifications for the analysis of pulmonary 
function (Quark PFT), cardiopulmonary exercise test-
ing (CPET Quark) and the determination of resting 
energy expenditure (Quark RMR) and launched the 
plethysmograph cabin (QBOX). These improvements 
were brought about by applying innovative approach-
es to user-driven input while marrying ICT solutions 
with effective product design. The products com-
bine hardware and firmware with interface control 
(a house-developed proprietary software suite called 
Omnia, which is encrypted for security and runs on 
Windows platforms).
Over the years, Cosmed has established strategic 
and business agreements with other companies and 
institutions, as both supplier and customer. These 
companies include Ergoline, Bosch, Adidas (Germany), 
U.S. Army, Apple Inc. (U.S.), Nihon Kohden (Japan), 
NORAV (Israel) and the University of Rome Tor Ver-
gata (Italy). Cosmed products have also been used in 
high-profile settings such as the James Bond film Sky-
fall, and the White House.
Reputation-Backed IP
Intellectual property plays a crucial role for Cosmed. 
The company has adopted a comprehensive approach 
to making the best use of patents, together with trade 
marks, design rights and copyright, to cover individual 
Performance diagnostics with spiroergometry using 
Cosmed’s wearable metabolic technology.
“In this market, you cannot claim to have cut-
ting-edge products and then let your customers 
discover that you don’t have any patents. You 
must have patents.”
Paolo Brugnoli,
Head of R & D and 
lead inventor, 
Cosmed
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products. Cosmed’s FitMate, for example, is protected 
by patents, registered as a trade mark, and uses copy-
right-protected software.
The worldwide market for metabolic devices has a 
limited number of players, which makes the competi-
tive environment more intimate. Because of these con-
ditions, reputation is of the essence and is boosted by 
a solid IP portfolio. Establishing a strong IP position is 
instrumental in growing the company’s market share, 
keeping other companies at bay and maintaining the 
capacity to enforce patents against infringers if neces-
sary. Cosmed has added to its portfolio by acquiring a 
small manufacturing company with an attractive set of 
products and patents.
Cosmed relies on its patent portfolio to build its 
reputation in the med-tech industry, where high-tech 
and IP are synonymous with reliability and quality. In 
doing so it assures users that its products are of a high 
standard and designed for a positive impact on human 
health and life. A strong IP portfolio also justifies pre-
mium pricing for pioneering technology. Cosmed’s 
brand name, market visibility and recognition are 
bolstered by a comprehensive IP portfolio, including 
trademarks and design rights that cover high-tech, us-
er-friendly products.
Dealing with Market Particularities
Before they can be put on the market, medical de-
vices must comply with regulatory requirements for 
safety and compatibility and must acquire certification. 
They must be reliable and affordable, and easy to use, 
clean and store. It can take up to 10 years for a product 
in the med-tech field to go from concept to market. 
Obtaining intellectual property rights early on creates 
safer conditions for investing in design and testing. 
Patents offer protection from imitation until the prod-
uct can eventually be sold.
Holistic IP Management
It is important to have strong, high-quality pat-
ents originating from sound IP management in 
which internal and external influences on the 
patent portfolio are under control. 
To develop innovative devices, Cosmed co-op-
erates with external experts and consulting firms 
specialising in healthcare 
product design. Here again, 
careful management of in-
tellectual property is very 
important to avoid loss of 
control of its innovative 
efforts and to prevent di-
lution or confusion with 
a third party’s knowledge 
and concepts. Co-operation 
is safer when IP ownership 
is clearly defined from the 
outset. Established IP creates “transactional securi-
ty,” which makes parties more comfortable sharing 
information and open to co-development efforts 
that do not impinge on the proprietary knowledge 
and expertise of partners.
Positive Side Effects
Owning IP gives Cosmed a competitive advantage 
in public procurement bids, since the uniqueness of 
products protected by patents is one of the criteria 
that public administration bodies in Europe can ap-
ply in their bidding procedures for the purchase of 
products directly from dedicated suppliers.
Under the optional “patent box” tax regime re-
cently introduced in Italy, and which also exists in 
similar form in many other countries, Cosmed has 
applied to the tax authorities for a so-called ruling 
agreement, which would give the company an ex-
tended tax break based on the contribution that 
its IP portfolio makes to its revenues. Although the 
agreement is still being negotiated, it is expected 
that Cosmed’s large and composite IP portfolio will 
result in significant benefits.
Last but not least, IP is instrumental in contrib-
uting to Cosmed’s equity value. The company is 
family-owned and its financial position is rock-sol-
id. While there are no plans to sell the company or 
go public, senior management is always looking to 
boost corporate value. The company’s IP is a crucial 
component of its intangible assets, as it helps to in-
crease the visibility of R&D investments for poten-
tial investors and financial analysis while reinforcing 
Cosmed’s credit rating.
Cosmed’s K5—
A Wearable Metabolic System
Cosmed’s K5, a wearable metabolic system designed 
for measuring metabolic parameters both in the field 
and in the laboratory.
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User-Centred Strategy that Reduce Risks
Filing for IP protection comes with risk. Drafting 
and validating patent applications at national level is 
expensive, especially if it is not yet clear whether the 
product will ever reach the market or have a satisfac-
tory uptake. To reduce such risks, Cosmed goes about 
product development with a user-centred approach 
and bottom-up design that aims to address the needs 
and requirements of users while realising spearhead 
products. When looking at user applicability, the com-
pany searches competitors’ patents, both as a source of 
information, to improve on existing designs, as well as 
to assess freedom to operate (FTO) and avoid infring-
ing third-party patents.
Prior Art Searches 
In-depth prior art searches must be conducted 
early in the creative process, before research be-
gins, and then professionally verified once the 
patent application has been drafted.
Cosmed’s traditional business model is based on de-
vice sales, so keeping alignment with the technology 
roadmap, products and patents, as well as other types 
of IP, has always been central to its IP strategy. Occa-
sionally, patent applications are filed for elements such 
as disposable parts rather than for entirely new devic-
es, which can offer a significant market in high-volume 
sales. In this case, intellectual property becomes instru-
mental in protecting post-sale markets that include the 
supply of spare parts and maintenance services.
IP Management that Works
Because of budgetary constraints and uncertainty in 
relation to new product development, Cosmed exer-
cises caution and foresight in its patenting decisions, 
particularly when it comes to protection in multiple 
countries. It uses an external IP firm to check that in-
ventions are properly disclosed, to draft and prosecute 
patents, and to interact with patent authorities world-
wide. The firm was carefully selected for its excel-
lence, since it is vital to have high-quality patents that 
can be enforced in court. Strategic decisions about IP 
are taken by Paolo Brugnoli, head of the R&D Depart-
ment and lead inventor of all Cosmed’s patents, who 
has a direct report to the CEO.
Looking at the entire value chain from R&D to mar-
ket entry, Cosmed conducts a number of activities 
in-house, from FTO analyses to prior art searches. 
When a potential invention is identified, the company 
sends a report to its IP firm for an initial evaluation, 
after which Paolo Brugnoli makes the final decision 
on whether or not to file. The IP attorneys then draft 
an application, which is reviewed by Cosmed before 
being filed.
External IP Support
IP strategy cannot be outsourced, but external 
expertise and support is important for feedback 
and for implementing strategic choices.
There are no formal guidelines for IP management 
within Cosmed, since too much formalisation is per-
ceived as a hindrance to creativity, but an informal in-
ternal procedure is in-place. Through exposure to cer-
tification and quality control procedures, the company 
has learned how to manage complex processes, while 
its operations have been successfully kept lean.
Patent Filing Strategy for the Future
In the past, Cosmed has filed patent applications in 
Italy to earn a priority date and then extended them 
to U.S. and EP levels, and on occasion to China and Ja-
pan. At European level, validation decisions are driven 
by budgetary considerations, and the more appealing 
markets are typically those where Cosmed has direct 
sales through subsidiaries, although the European 
market is turning out to extend into countries beyond 
those where the patents have been validated to date. 
Recently, at least where it is clear that a product could 
Aerogen Vibronic®—Technology Profile
The K5 is the fourth generation of Cosmed’s family of 
wearable metabolic systems developed and designed 
for the measurement of metabolic parameters such 
as oxygen production (VO2), carbon dioxide pro-
duction (VCO2), ventilation, energy expenditure and 
heart rate. The K5 unit contains 3D motion sensors 
and GPS in order to combine metabolic analysis with 
speed, cadence, stride, steps and related parame-
ters. It also includes the IntelliMET patented dual gas 
sampling system (EP2769673), which allows users to 
choose between two different breathing modes. The 
mixing chamber mode can be used to obtain average 
measurements of oxygen and carbon dioxide con-
sumption within a number of breathing cycles and 
is suitable for use on athletes. The breath-by-breath 
mode can be used to carry out instantaneous meas-
urements of consumption during each breathing cy-
cle and is suitable for applications in the clinical field.
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have a wider market penetration, Cosmed has used the 
EP as a priority filing, to save money and time. The 
Unitary Patent will present an opportunity to cover 
an even larger market at European level, at a reduced 
cost. The savings can then be parlayed into future pat-
ents, thus reinforcing Cosmed’s portfolio.
Although its patent portfolio is not huge, Cosmed 
has some difficulty coping with its management and 
the associated costs, particularly at the validation lev-
el, when budget constraints become more demanding 
and costs increase as a result of translations, renewal 
fees, issuance fees, validation fees at national levels, 
and so on. The Unitary Patent is likely to make the 
decision-making process much easier. Moreover, a 
system that allows for savings and wider geographic 
coverage will reinforce Cosmed’s position on the Euro-
pean market, where its patent protection is currently 
limited to five countries (Italy, Germany, United King-
dom, France, the Netherlands), while its products are 
sold all over Europe.
Patent Portfolio Management 
Budget considerations are necessary. It is impor-
tant to reduce costs without sacrificing quality 
when creating and maintaining a portfolio, as 
long as it reinforces the business case and the 
patent system allows for it.
Although Cosmed hopes to avoid litigation in the 
future, the prospect of a Unified Patent Court is appre-
ciated, as past experience with enforcing patents has 
made management aware of the disruption litigation 
can introduce. Litigation in multiple countries could 
have had even more disastrous consequences. With 
strong patents to enforce, the Unified Patent Court 
seems to be the best solution and will also be a deter-
rent for potential infringers.
When it comes to the future, Paolo Brugnoli, an elec-
tronic engineer by training, has no doubt that the Uni-
tary Patent system will provide more benefits, such as 
reduced administrative steps, which are his responsibil-
ity. It is also expensive for the company since he, as a 
senior manager, has to facilitate strategic decisions, as 
well as handle the particulars of the patent administra-
tive procedure. Of course, the company could reorgan-
ise internally and have someone else be responsible for 
patents, but the current set-up has the advantage of hav-
ing the head of R&D directly involved in IP management 
and in close contact with the corporate CEO. ■
Available at Social Science Research Network (SSRN):
https://ssrn.com/abstract=3068838
Cosmend’s Bod Pod Gold Standard
Cosmed’s Bod Pod Gold Standard is a body composi-
tion (fat and fat-free mass) tracking system that uses 
whole body densitometry.
Company Profile
Cosmed S.R.L.
• Headquarters: Albano Laziale, Italy
• Year of establishment: 1980
• Staff: 120
• Turnover: EUR 17 million
• www.cosmed.com
Products/Services
Biomedical devices for the measurement of rest-
ing metabolic rate, maximum oxygen consump-
tion and spirometric parameters. The products 
are a combination of hardware and firmware with 
interface control.
Market and Technical Area
Biomedical devices and software.
Customers
Hospital care, universities and research centres, nu-
trition clinics, sports teams.
Selected Awards
2013 Product of Outstanding Interest
   (European Respiratory Society)
Patent Portfolio
Three patent families, e.g. EP2769673, EP0196396
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